CY1115487T1 - Χρησιμοποιηση αμισουλπριδης για τη θεραπεια προκαλουμενης απο χημειοθεραπεια ναυτιας και εμετου - Google Patents

Χρησιμοποιηση αμισουλπριδης για τη θεραπεια προκαλουμενης απο χημειοθεραπεια ναυτιας και εμετου

Info

Publication number
CY1115487T1
CY1115487T1 CY20141100657T CY141100657T CY1115487T1 CY 1115487 T1 CY1115487 T1 CY 1115487T1 CY 20141100657 T CY20141100657 T CY 20141100657T CY 141100657 T CY141100657 T CY 141100657T CY 1115487 T1 CY1115487 T1 CY 1115487T1
Authority
CY
Cyprus
Prior art keywords
treatment
chemotherapy
amisulpridis
marine
vehicle
Prior art date
Application number
CY20141100657T
Other languages
English (en)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Nicola Cooper
Gabriel Fox
Original Assignee
Acacia Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115487(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Limited filed Critical Acacia Pharma Limited
Publication of CY1115487T1 publication Critical patent/CY1115487T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η αμισουλπρίδη χρησιμοποιείται στη θεραπεία ναυτίας, και εμετού προκαλούμενων από χημειοθεραπεία με ακτινοβολία.
CY20141100657T 2010-03-11 2014-08-14 Χρησιμοποιηση αμισουλπριδης για τη θεραπεια προκαλουμενης απο χημειοθεραπεια ναυτιας και εμετου CY1115487T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
EP12188047.0A EP2567690B1 (en) 2010-03-11 2011-03-10 Use of amisulpride for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
CY1115487T1 true CY1115487T1 (el) 2017-01-04

Family

ID=42136792

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20141100657T CY1115487T1 (el) 2010-03-11 2014-08-14 Χρησιμοποιηση αμισουλπριδης για τη θεραπεια προκαλουμενης απο χημειοθεραπεια ναυτιας και εμετου
CY20141100656T CY1115485T1 (el) 2010-03-11 2014-08-14 Χρησιμοποιηση αμισουλπριδης για τη θεραπεια μετεγχειρητικης ναυτιας και εμετου
CY20181100416T CY1120170T1 (el) 2010-03-11 2018-04-18 Χρησιμοποιηση αμισουλπριδης για τη θεραπεια επαγομενης απο οπιοειδη ναυτιας και εμετου

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20141100656T CY1115485T1 (el) 2010-03-11 2014-08-14 Χρησιμοποιηση αμισουλπριδης για τη θεραπεια μετεγχειρητικης ναυτιας και εμετου
CY20181100416T CY1120170T1 (el) 2010-03-11 2018-04-18 Χρησιμοποιηση αμισουλπριδης για τη θεραπεια επαγομενης απο οπιοειδη ναυτιας και εμετου

Country Status (27)

Country Link
US (11) US9084765B2 (el)
EP (3) EP2796171B1 (el)
JP (2) JP5886213B2 (el)
KR (1) KR101738201B1 (el)
CN (1) CN102892407B (el)
AU (1) AU2011225898B2 (el)
BR (1) BR112012022746B1 (el)
CA (1) CA2792392C (el)
CY (3) CY1115487T1 (el)
DK (3) DK2796171T3 (el)
EA (1) EA030335B1 (el)
ES (3) ES2496092T3 (el)
GB (1) GB201004020D0 (el)
HK (1) HK1179152A1 (el)
HR (3) HRP20140744T1 (el)
HU (1) HUE037088T2 (el)
IL (1) IL221746A (el)
LT (1) LT2796171T (el)
MX (3) MX370629B (el)
NO (1) NO2796171T3 (el)
NZ (1) NZ602279A (el)
PL (3) PL2544657T3 (el)
PT (3) PT2567690E (el)
RS (3) RS53466B (el)
SI (3) SI2567690T1 (el)
SM (2) SMT201400126B (el)
WO (1) WO2011110854A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
EP3344962A4 (en) 2015-09-02 2019-03-13 California Institute of Technology METHOD AND APPARATUS FOR SPECTROSCOPIC DETECTION OF LOW HYDROGEN SULFIDE CONCENTRATIONS GASEOUS
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
EP3980008A4 (en) * 2019-06-04 2023-06-28 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
SG11202113266YA (en) * 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
CN115867271A (zh) * 2020-07-06 2023-03-28 阿卡西亚制药有限公司 术后恶心和呕吐的疗法
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
BRPI0707324A2 (pt) * 2006-01-27 2011-05-03 Eurand Inc sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
WO2009089494A2 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
AU2011225898A1 (en) 2012-10-04
SMT201400127B (it) 2015-05-05
GB201004020D0 (en) 2010-04-21
RS53466B (en) 2014-12-31
BR112012022746B1 (pt) 2021-09-28
JP2013522181A (ja) 2013-06-13
US9545426B2 (en) 2017-01-17
EP2567690A1 (en) 2013-03-13
US20130022689A1 (en) 2013-01-24
DK2544657T3 (da) 2014-08-11
CN102892407B (zh) 2016-03-23
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10
US20180042896A1 (en) 2018-02-15
SI2567690T1 (sl) 2014-12-31
WO2011110854A2 (en) 2011-09-15
PT2567690E (pt) 2014-09-03
US20200093792A1 (en) 2020-03-26
DK2796171T3 (en) 2018-05-07
JP2016028090A (ja) 2016-02-25
SMT201400126B (it) 2015-05-05
CA2792392A1 (en) 2011-09-15
EP2796171B1 (en) 2018-01-31
EP2544657B1 (en) 2014-07-16
CN102892407A (zh) 2013-01-23
KR20130045241A (ko) 2013-05-03
US9119836B2 (en) 2015-09-01
ES2496092T3 (es) 2014-09-18
US10085970B2 (en) 2018-10-02
ES2496099T3 (es) 2014-09-18
HRP20140744T1 (hr) 2014-09-26
CY1115485T1 (el) 2017-01-04
HUE037088T2 (hu) 2018-08-28
HRP20180436T1 (hr) 2018-05-04
JP6279526B2 (ja) 2018-02-14
EA030335B1 (ru) 2018-07-31
RS57032B1 (sr) 2018-05-31
MX2019015396A (es) 2020-02-07
US20180353473A1 (en) 2018-12-13
EP2796171A1 (en) 2014-10-29
NO2796171T3 (el) 2018-06-30
US20170087128A1 (en) 2017-03-30
EP2544657A2 (en) 2013-01-16
HK1179152A1 (zh) 2013-09-27
PT2544657E (pt) 2014-09-03
AU2011225898B2 (en) 2014-07-03
US20140147517A1 (en) 2014-05-29
ES2665418T3 (es) 2018-04-25
US20210228543A1 (en) 2021-07-29
JP5886213B2 (ja) 2016-03-16
PL2544657T3 (pl) 2014-10-31
KR101738201B1 (ko) 2017-05-19
US10525033B2 (en) 2020-01-07
LT2796171T (lt) 2018-05-10
NZ602279A (en) 2014-08-29
SI2796171T1 (en) 2018-05-31
US9084765B2 (en) 2015-07-21
BR112012022746A2 (pt) 2016-07-05
HRP20140745T1 (hr) 2014-09-26
DK2567690T3 (da) 2014-08-11
RS53467B (en) 2014-12-31
MX2012010411A (es) 2012-11-30
PT2796171T (pt) 2018-04-24
US20230144973A1 (en) 2023-05-11
EP2567690B1 (en) 2014-07-16
CY1120170T1 (el) 2018-12-12
IL221746A (en) 2017-03-30
US20130022688A1 (en) 2013-01-24
US20220296570A1 (en) 2022-09-22
US20150335616A1 (en) 2015-11-26
EA201290833A1 (ru) 2013-09-30
CA2792392C (en) 2018-06-19
US9889118B2 (en) 2018-02-13
US8686019B2 (en) 2014-04-01
PL2567690T3 (pl) 2014-11-28
MX370629B (es) 2019-12-18
SI2544657T1 (sl) 2014-12-31

Similar Documents

Publication Publication Date Title
CY1115487T1 (el) Χρησιμοποιηση αμισουλπριδης για τη θεραπεια προκαλουμενης απο χημειοθεραπεια ναυτιας και εμετου
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
AR077237A1 (es) Polimeros colorantes
CY1118250T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
WO2011137429A3 (en) Synthesis of four coordinated palladium complexes and their applications in light emitting devices thereof
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
EA201792682A1 (ru) Пирролбензодиазепины и их конъюгаты
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
AR080147A1 (es) Polimeros colorantes
EA201390074A1 (ru) 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
CY1118062T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης
AR084330A1 (es) Polimeros a base de etileno y procesos para formarlos
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
CR20110553A (es) Terapia complementaria contra el cáncer
BR112016002782A2 (pt) métodos para controlar polimerizações de olefina de catalisador de metaloceno duplo com um composto de álcool
EA201490559A1 (ru) Композиция для лечения свища
TW201614889A (en) Porous films for use in light-emitting devices
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
EA201500744A1 (ru) Комбинированная терапия с использованием антител к her3 и к her2
CY1118968T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
BR112012033231A2 (pt) peças revestidas e seu uso
CY1118912T1 (el) Πηκτωματουμενο κολλαγονο και μεσο για τη διαθεση αυτου